Plk Antibody (AZ27): sc-53419
- Plk Antibody (AZ27) is a mouse monoclonal IgG2b provided at 200 µg/ml
- raised against Plk of Xenopus origin
- recommended for detection of Plk of mouse, rat, human and Xenopus origin by WB and IP
- See Plk (F-8): sc-17783 for Plk antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for Plk Antibody (AZ27). This work is in progress.
QUICK LINKS
SEE ALSO...
Plk Antibody (AZ27) is a mouse monoclonal IgG2b light chain antibody that detects Plk in mouse, rat, and human samples through applications such as western blotting (WB) and immunoprecipitation (IP). Plk, or polo-like kinase, plays a crucial role in cell cycle regulation, particularly during the transition from the G2 phase to mitosis, where Plk is essential for the proper functioning of the mitotic spindle. Plk activity is tightly regulated, with Plk levels peaking at the onset of mitosis, which is vital for ensuring accurate chromosome segregation and preventing aneuploidy. Plk presence is particularly notable in mitotically active tissues, including the colon and placenta, as well as in various tumors, suggesting Plk potential as a biomarker for cell proliferation and cancer progression. Anti-Plk antibody (AZ27) provides a reliable tool for researchers investigating the dynamics of cell division and the implications of Plk in oncogenesis, enabling deeper insights into the mechanisms of cell cycle regulation and associated pathologies.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Plk Antibody (AZ27) References:
- Mutations in the Plk gene lead to instability of Plk protein in human tumour cell lines. | Simizu, S. and Osada, H. 2000. Nat Cell Biol. 2: 852-4. PMID: 11056542
- MiR-126 negatively regulates PLK-4 to impact the development of hepatocellular carcinoma via ATR/CHEK1 pathway. | Bao, J., et al. 2018. Cell Death Dis. 9: 1045. PMID: 30315225
- Discovery of Inhibitors of Aurora/PLK Targets as Anticancer Agents. | Qi, B., et al. 2019. J Med Chem. 62: 7697-7707. PMID: 31381325
- PLK-1 promotes the merger of the parental genome into a single nucleus by triggering lamina disassembly. | Velez-Aguilera, G., et al. 2020. Elife. 9: PMID: 33030429
- Pericentriolar matrix (PCM) integrity relies on cenexin and polo-like kinase (PLK)1. | Aljiboury, A., et al. 2022. Mol Biol Cell. 33: br14. PMID: 35609215
- Unusually High Affinity of the PLK Inhibitors RO3280 and GSK461364 to HSA and Its Possible Pharmacokinetic Implications. | Fernández-Sainz, J., et al. 2023. Mol Pharm. 20: 1631-1642. PMID: 36812406
- Methylation of PLK-1 Potentially Drives Bendamustine Resistance in Leukemia Cells. | Itabashi, T., et al. 2024. J Nippon Med Sch. 91: 162-171. PMID: 38072417
- Building the centrosome: PLK-1 controls multimerization of SPD-5. | Conduit, P. 2024. J Cell Biol. 223: PMID: 38456968
- Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. | Holtrich, U., et al. 1994. Proc Natl Acad Sci U S A. 91: 1736-40. PMID: 8127874
- Plk is an M-phase-specific protein kinase and interacts with a kinesin-like protein, CHO1/MKLP-1. | Lee, KS., et al. 1995. Mol Cell Biol. 15: 7143-51. PMID: 8524282
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Plk Antibody (AZ27) | sc-53419 | 200 µg/ml | $322.00 |